Program
remternetug
Also written as “LY3372993”, “Remternetug” and “Remternetug (IV)”.
Its studies are mostly in Alzheimer Disease, led by Eli Lilly.
Furthest: phase 3, since Jul 14, 20226 company-led studies, 1 open or runningNext primary completion: Apr 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 61 open or running | phase 3since Jul 14, 2022 | Oct 24, 2018 | Apr 2029phase 3 · NCT06653153 |
- Named in Eli Lilly’s own pipeline as
Remternetug
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 24, 2018First study: phase 1 study in Alzheimer DiseaseFirst studyNCT03720548 · 36 enrolled · United States
- Jun 26, 2020Phase 1 study in Alzheimer DiseaseNCT04451408 · 139 enrolled · United States, Japan
- Jul 14, 2022Phase 3 study in Alzheimer DiseaseNCT05463731 · 1,667 enrolled · United States, Japan
- Oct 21, 2024Phase 3 study in Alzheimer DiseaseNCT06653153 · 1,400 enrolled · United States, Australia, Canada and more
- Jun 24, 2025Phase 1 study in HealthyNCT07056309 · 72 enrolled · United States
- Jan 9, 2026Phase 1 study in HealthyNCT07346495 · 24 enrolled · China
Ahead
- Apr 2029Primary completion: phase 3 study in Alzheimer DiseaseNCT06653153
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07346495Healthy · China | 1 | Completed | Aug 4, 2026 | 24 |
| NCT07056309Healthy · United States | 1 | Completed | Dec 15, 2025 | 72 |
| NCT06653153Alzheimer Disease · United States, Australia, Canada and more | 3 | Active, not recruiting | Apr 2029 | 1,400 |
| NCT05463731Alzheimer Disease · United States, Japan | 3 | Completed | Apr 24, 2024 | 1,667 |
| NCT04451408Alzheimer Disease · United States, Japan | 1 | Completed | Nov 18, 2024 | 139 |
| NCT03720548Alzheimer Disease · United States | 1 | Completed | May 14, 2019 | 36 |
How it is read
Names in the registry
- “LY3372993”, 3 entries
- “Remternetug”, 1 entry
- “Remternetug (IV)”, 1 entry
- “Remternetug (SC)”, 1 entry
- “Remternetug (Test)”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.